IDEMIA Announces the Appointment of Yann Delabrière as New Chairman of the Group
IDEMIA, the world leader in Augmented Identity in an increasingly digital world, sees the chairmanship of its Supervisory Board renewed with the promotion of Yann DELABRIÈRE, former Vice-Chairman of the group.
Former CEO of Faurecia and current Chairman of the Management Board of Zodiac Aerospace, Yann DELABRIERE will replace Marwan LAHOUD, who becomes Vice-Chairman of the group. These changes take effect immediately.
In May 2017, Advent International invested alongside Bpifrance to bring together the complementary strengths of Safran I&S (Morpho) and Oberthur Technologies (OT). Combining Morpho’s leadership in end-to-end biometric and identity solutions with OT’s leadership in embedded digital security, the new IDEMIA identity was unveiled on 28th September 2017.
It is the global leader in Augmented Identity for an increasingly digital world, with a view to provide citizens and consumers with end-to-end full-secured solutions, when they interact, pay, connect, travel and vote.
“As the new Chairman of IDEMIA's Supervisory Board, I am very pleased to continue the work initiated by Marwan LAHOUD and all the other members, since OT and Morpho joined forces, to build the group's leadership. In a fast-changing industry, I know we can rely on the talented and skilled leaders who compose the recently announced top-management team to deliver upon the CEO Didier LAMOUCHE’s strategic vision”, declares Yann DELABRIÈRE.
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in Augmented Identity for an
increasingly digital world, with the ambition to empower citizens and
consumers alike to interact, pay, connect, travel and vote in ways that
are now possible in a connected environment.
Securing our identity
has become mission critical in the world we live in today. By standing
for Augmented Identity, we reinvent the way we think, produce, use and
protect this asset, whether for individuals or for objects. We ensure
privacy and trust as well as guarantee secure, authenticated and
verifiable transactions for international clients from Financial,
Telecom, Identity, Public Security and IoT sectors.
OT (Oberthur
Technologies) and Safran Identity & Security (Morpho) have joined forces
to form IDEMIA. With close to $3 billion in revenues and 14,000
employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
About Advent International
Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in 325 private equity transactions in 40 countries and as of December 31, 2016, it had €39 billion in assets under management. With offices on four continents, Advent has established a globally integrated team of over 180 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; healthcare; industrial; retail, consumer and leisure; and technology, media and telecom. After more than 30 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies.
For further information, visit: www.adventinternational.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180129005765/en/
Contact information
Media
IDEMIA (Havas Paris)
Hanna Sebbah :
+33 6 63 73 30 30
Manon Gaudefroy : +33 6 85 30 60 02
Alisa
Gribe-Marquis : + 33 6 03 12 93 13
E-mail : idemia@havas.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SBC Medical added to membership of Russell 3000 ® Index28.6.2025 02:30:00 EEST | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical”), a global franchise and provider of services for aesthetic clinics, has been added as a member of the broad-market Russell 3000® Index, effective after the US market opens on June 30, as part of the 2025 Russell indexes reconstitution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250608244276/en/ Yoshiyuki Aikawa-Director (Chairman), CEO Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000®Index as well as the appropriate growth and value style indexes. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. According to the data as of the end of June 2024, about $10.6 trillion in assets are benchmarked against the Russell US indexes, which belong to
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse27.6.2025 23:44:00 EEST | Press release
Altimetrik, a pure-play AI, Data and Digital engineering solutions company, today announced the signing of a definitive agreement to acquire SLK Software (“SLK”), a global technology services firm focused on delivering AI, intelligence automation and analytics solutions. The acquisition will further strengthen Altimetrik’s end-to-end enablement services and expand its customer reach, with a clear path to accelerate towards Altimetrik’s goal of reaching $1billion in annual revenue. The transaction remains subject to customary closing conditions and is expected to close in the second half of 2025. Financial details were not disclosed. Founded in 2000, SLK is recognized as a leader in the tech industry, and for its commitment to create innovative digital solutions. This strategic acquisition will significantly enhance the scale of Altimetrik’s capabilities, bringing together Altimetrik’s AI-first, platform-native engineering model and SLK’s full technology services stack that will further
PRD Therapeutics Announces Initiation of First-in-Human Study for PRD00127.6.2025 17:00:00 EEST | Press release
PRD Therapeutics, Inc., a clinical stage company focused on the development of novel lipid metabolism regulators targeting homozygous familial hypercholesterolemia (HoFH) and metabolic dysfunction associated fatty liver disease (MASH/MASLD), today announced that the company recently initiated dosing in a First-in-Human (FIH) clinical trial of PRD001, a first-in-class SOAT2 (formerly known as ACAT2) selective inhibitor. “We are excited to initiate dosing in this clinical trial of PRD001. Many clinical trials have been conducted on SOAT1/2 dual or SOAT1 selective inhibitors, but this is the first clinical trial of an SOAT2 selective inhibitor” said Kanji Hosoda, Ph.D., CEO and co-founder of PRD Therapeutics. “Several results with SOAT1 or 2 knockout mice have been published, suggesting that knocking out or inhibiting only SOAT2 is crucial to demonstrate safety and efficacy. PRD001 is the world's first and only SOAT2-selective inhibitor and is expected to exhibit safety and efficacy in hu
STEMCELL Technologies Introduces STEMprep™ Tissue Dissociator System to Accelerate Research Discoveries27.6.2025 15:00:00 EEST | Press release
To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627342791/en/ To help scientists accelerate their workflows, STEMCELL Technologies has commercially launched the STEMprep™ Tissue Dissociator System—a new benchtop instrument that automates, standardizes, and streamlines tissue dissociation, the process of breaking down tissue samples into single-cell suspensions for research purposes. “Tissue dissociation is incredibly important for making advancements in research fields, like cancer and immunology, yet this manual process demands significant time and effort and can lead to inconsistent results,” said Dr. A
Pure Lithium Founder & CEO Emilie Bodoin Recognized for Trailblazing Woman of the Year at 2025 Volta Foundation Awards at 17 th Annual Fastmarkets Lithium Supply and Battery Raw Materials Conference27.6.2025 13:00:00 EEST | Press release
Pure Lithium Corporation, a disruptive vertically integrated lithium metal battery technology company, is pleased to announce that its Founder, Chairman & CEO, Emilie Bodoin received special recognition for Trailblazing Woman of the Year Award Sponsored by ExxonMobil at the 2025 Fastmarkets Volta Awards Ceremony, in Las Vegas, Nevada on June 24. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250627170164/en/ This award celebrates an exceptional female leader who has demonstrated outstanding leadership, vision, and impact within her industry. It recognizes achievements in driving innovation, fostering diversity, and inspiring others while making significant contributions to her organization. “I am truly honored to receive special recognition for this award. One of the best things about my role is the opportunity to lead by example and encourage and inspire women and girls who may not yet recognize their potential. To all of m
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom